Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Astria Therapeutics Inc (ATXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: ATXS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $28.67
1 Year Target Price $28.67
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 115.38% | Avg. Invested days 53 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 349.89M USD | Price to earnings Ratio - | 1Y Target Price 28.67 |
Price to earnings Ratio - | 1Y Target Price 28.67 | ||
Volume (30-day avg) 9 | Beta 0.38 | 52 Weeks Range 3.56 - 12.92 | Updated Date 07/8/2025 |
52 Weeks Range 3.56 - 12.92 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.56% | Return on Equity (TTM) -32.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 155215157 | Price to Sales(TTM) - |
Enterprise Value 155215157 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.57 | Shares Outstanding 56434200 | Shares Floating 30074360 |
Shares Outstanding 56434200 | Shares Floating 30074360 | ||
Percent Insiders 0.49 | Percent Institutions 106.43 |
Upturn AI SWOT
Astria Therapeutics Inc
Company Overview
History and Background
Astria Therapeutics, Inc., formerly Integral Molecular, Inc., is a biopharmaceutical company. Founded in 2018, it focuses on developing therapies for rare and life-threatening allergic and immunological diseases.
Core Business Areas
- Angioedema: Astria is focused on developing STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, for the treatment of hereditary angioedema (HAE).
Leadership and Structure
The leadership team includes Jill C. Milne, Ph.D., Chief Executive Officer, and Andrea Matthews, Chief Financial Officer. The company operates with a standard organizational structure common to biopharmaceutical companies.
Top Products and Market Share
Key Offerings
- STAR-0215: STAR-0215 is Astria's lead product candidate, a monoclonal antibody inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Market share data is not yet applicable as the product is still in clinical development. Competitors include Takeda (TAK) with Takhzyro, BioCryst Pharmaceuticals (BCRX) with Orladeyo, and CSL Behring with Haegarda and Berinert.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. The HAE market is growing with increasing awareness and diagnosis rates.
Positioning
Astria is positioned as an emerging player in the HAE market, aiming to provide a differentiated treatment option with STAR-0215.
Total Addressable Market (TAM)
The global hereditary angioedema (HAE) market is estimated to be in the billions. Astria is seeking to capture a share of this market with a novel treatment option for patients who may benefit from less frequent injections.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action (STAR-0215)
- Experienced Management Team
- Focus on a Specific Therapeutic Area (HAE)
Weaknesses
- Single Product Candidate Dependence
- Early Stage Clinical Development
- High Cash Burn Rate
Opportunities
- Positive Clinical Trial Results
- Expansion to other Angioedema Types
- Partnerships with Larger Pharmaceutical Companies
Threats
- Competition from Established HAE Therapies
- Clinical Trial Failures
- Regulatory Hurdles
- Patent Challenges
Competitors and Market Share
Key Competitors
- TAK
- BCRX
- CSL
Competitive Landscape
Astria's advantage lies in potentially providing a less frequent injection option. Disadvantages include being a smaller company competing against established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's stock price, influenced by pipeline progress and financial performance.
Future Projections: Future growth is dependent on the successful development and commercialization of STAR-0215.
Recent Initiatives: Recent initiatives include advancing STAR-0215 through clinical trials, and presenting data at scientific conferences.
Summary
Astria Therapeutics is a clinical-stage biopharmaceutical company focused on HAE. Success hinges on clinical trial outcomes for STAR-0215. Key challenges include competing with established therapies and managing cash flow. The company needs to carefully manage its clinical trials and regulatory pathways, while also exploring ways to expand its product pipeline and revenue streams to ensure long-term success. Its novel approach to reducing injection frequency could be a significant advantage, if clinical data supports it.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated. Clinical trial results are subject to change. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Astria Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-06-25 | Co-Founder, CEO, President & Director Ms. Jill C. Milne Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.astriatx.com |
Full time employees 78 | Website https://www.astriatx.com | ||
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.